ES2056108T3 - Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica. - Google Patents

Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.

Info

Publication number
ES2056108T3
ES2056108T3 ES88305934T ES88305934T ES2056108T3 ES 2056108 T3 ES2056108 T3 ES 2056108T3 ES 88305934 T ES88305934 T ES 88305934T ES 88305934 T ES88305934 T ES 88305934T ES 2056108 T3 ES2056108 T3 ES 2056108T3
Authority
ES
Spain
Prior art keywords
biological activity
molecula
antibody
complex
protect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88305934T
Other languages
English (en)
Inventor
Ezekiel Y Shami
Aser Rothstein
Mohabir Ramjeesingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrisens Ltd
Original Assignee
Hybrisens Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrisens Ltd filed Critical Hybrisens Ltd
Application granted granted Critical
Publication of ES2056108T3 publication Critical patent/ES2056108T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PUEDE PRODUCIR UN COMPLEJO QUE COMPRENDE (I) UNA MOLECULA QUE TIENE UNA ACTIVIDAD BIOLOGICA E (II) UN ENTE ANTICUERPO QUE RECONOCE LA MOLECULA, QUE MUESTRA LA ACTIVIDAD BIOLOGICA, QUE ES RESISTENTE A LA INACTIVACION EN RELACION CON LA DE LA MOLECULA. LA MOLECULA BIOLOGICAMENTE ACTIVA PUEDE SER UN ENZIMA, POR EJEMPLO, Y SE PUEDE UTILIZAR PARA PRODUCIR UN COMPLEJO CON UN ANTICUERPO O PROTEINA ENLAZANTE DE ANTIGENO, QUE RESISTE LA INACTIVACION QUE RESULTA DE UN PROCESO FISICO, QUIMICO O BIOLOGICO. ASI, EL COMPLEJO RESISTENTE A LA ACTIVACION MUESTRA ACTIVIDAD PROLONGADA BAJO CONDICIONES CARACTERIZADAS POR TEMPERATURA DE ROTURA, EN PRESENCIA DE UN ENZIMA PROTEOLITICO, PH DE ROTURA, LA PRESENCIA DE UN AGENTE OXIDANTE Y/O LA PRESENCIA DE UN ALCOHOL, ENTRE OTROS.
ES88305934T 1987-07-07 1988-06-30 Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica. Expired - Lifetime ES2056108T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7186187A 1987-07-07 1987-07-07
US18253088A 1988-04-18 1988-04-18
US20574888A 1988-06-21 1988-06-21

Publications (1)

Publication Number Publication Date
ES2056108T3 true ES2056108T3 (es) 1994-10-01

Family

ID=27371979

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88305934T Expired - Lifetime ES2056108T3 (es) 1987-07-07 1988-06-30 Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.

Country Status (7)

Country Link
EP (1) EP0298654B1 (es)
JP (1) JPH01138461A (es)
AT (1) ATE106250T1 (es)
AU (1) AU1865288A (es)
DE (1) DE3889783T2 (es)
DK (1) DK375188A (es)
ES (1) ES2056108T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
ES2148144T3 (es) * 1990-11-20 2000-10-16 Dade Behring Marburg Gmbh Procedimiento para la estabilizacion de conjugados de enzima.
AU6953796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled cellulolytic activity
AU6849696A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled proteolytic activity
AU6849796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled enzymatic activity
AU6777296A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled lipolytic activity
WO1998007816A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising oxido-reductase antibody
WO1998007818A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled amylolytic activity
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
JPWO2005094881A1 (ja) * 2004-03-30 2008-02-14 武田薬品工業株式会社 抗体医薬
EP1841452B8 (en) * 2004-10-08 2014-06-11 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
ATE58479T1 (de) * 1985-12-28 1990-12-15 Nippon Hypox Lab Inc Albumin-komplex.
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides

Also Published As

Publication number Publication date
JPH01138461A (ja) 1989-05-31
DK375188D0 (da) 1988-07-06
ATE106250T1 (de) 1994-06-15
DE3889783D1 (de) 1994-07-07
DE3889783T2 (de) 1994-09-08
AU1865288A (en) 1989-01-12
DK375188A (da) 1989-01-08
EP0298654A3 (en) 1990-02-07
EP0298654B1 (en) 1994-06-01
EP0298654A2 (en) 1989-01-11

Similar Documents

Publication Publication Date Title
AR243234A1 (es) Un gen quimerico modificado que codifica una proteina insecticida de bacillus thuringiensis,un vector que lo contiene, y un metodo para mejorar la expresion de un gen heterologo.
ES2061512T3 (es) Polipeptidos de nor-estatina y nor-cicloestatina.
FI883082A0 (fi) Konstruering av syntetisk dna och dess anvaendning i syntes av stora polypeptider.
ES2097781T3 (es) Metodo y composicion para la determinacion de iones cloruro en fluidos.
ES2056817T3 (es) Transformacion de trichoderma.
ATE162221T1 (de) Herstellung von glukoseoxidase in rekombinanten systemen
DE69013520D1 (de) Stabile integration von dna in bakterielle genome.
DE3280150D1 (de) Mikroorganismen fuer den mikrobiellen abbau von schaedlichen organischen abfallstoffen in unschaedliche materialien.
DE3781732D1 (de) Mischungen von alpha-amylase zur verfluessigung von staerke.
TR199800046A2 (xx) Aktif maddeler yarat�lmas� i�in n�kleik asit olu�umu.
ES2181805T3 (es) Compuestos quimicos.
SE8801701D0 (sv) Production technology based on enzymic method
DE3751109D1 (de) Reagenzien zur Bestimmung von Peptidoglykan und beta-1,3-Glukan.
DE69736975D1 (de) Enzym mit galaktanaseaktivität
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ES2119283T3 (es) Proceso para producir 2-metil-1,4-naftoquinona.
EP0298654A3 (en) Use of antibody/antigen interactions to protect or modulate biological activity
DE59009945D1 (de) Mittel zur hemmung von hiv-proteasen.
ES2099714T3 (es) Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.
ES2091280T3 (es) Composicion detergente liquida que contiene lipasa y proteasa.
ES486658A1 (es) Procedimiento para el tratamiento de pellejos con enzimas proteoliticas
ES2000435A4 (es) Procedimiento de purificacion de antigenos proteinicos de bacterias que pertenecen al genero bordetella, en vista a la obtencion de una vacuna acelular.
KR910003114A (ko) 세팔로스포린 c를 글루타릴-7-아미노세팔로스포란산으로 효소 산화시키는 개선된 방법
DK0998549T3 (da) Anvendelse af enzymholdige opløsninger til rengøringen af gærings- eller lagringstanke
ES2071610T3 (es) Proteina l y sus subfragmentos, con actividad de union a inmunoglobulinas, un procedimiento para su preparacion, estuche de reactivos, composicion farmaceutica y una cepa de peptococcus magnus.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 298654

Country of ref document: ES